FDA Schedules Vaccines Panel On COVID Boosters As Questions Linger About Data Adequacy

 
• By Sarah Karlin-Smith

VRBPAC could help restore some confidence in any booster decision after White House moved ahead of FDA and CDC, but without hard outcomes data and no proven immune correlate of protection, support for Pfizer’s sBLA at the 17 September advisory committee meeting seems far from guaranteed.

third vaccine shot
FDA is moving fast to get Pfizer’s booster sBLA to an advisory committee just weeks after receiving the application • Source: Alamy

More from US FDA

More from Agency Leadership